BIOA
Price
$20.00
Change
-$0.15 (-0.74%)
Updated
Feb 5, 04:59 PM (EDT)
Capitalization
841.73M
42 days until earnings call
Intraday BUY SELL Signals
TLRY
Price
$7.06
Change
-$0.54 (-7.11%)
Updated
Feb 5, 04:59 PM (EDT)
Capitalization
886.62M
Intraday BUY SELL Signals
Interact to see
Advertisement

BIOA vs TLRY

Header iconBIOA vs TLRY Comparison
Open Charts BIOA vs TLRYBanner chart's image
BioAge Labs
Price$20.00
Change-$0.15 (-0.74%)
Volume$9.4K
Capitalization841.73M
Tilray Brands
Price$7.06
Change-$0.54 (-7.11%)
Volume$29.32K
Capitalization886.62M
BIOA vs TLRY Comparison Chart in %
View a ticker or compare two or three
VS
BIOA vs. TLRY commentary
Feb 06, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIOA is a Hold and TLRY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 06, 2026
Stock price -- (BIOA: $20.15 vs. TLRY: $7.60)
Brand notoriety: BIOA: Not notable vs. TLRY: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BIOA: 61% vs. TLRY: 34%
Market capitalization -- BIOA: $841.73M vs. TLRY: $886.62M
BIOA [@Pharmaceuticals: Generic] is valued at $841.73M. TLRY’s [@Pharmaceuticals: Generic] market capitalization is $886.62M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIOA’s FA Score shows that 1 FA rating(s) are green whileTLRY’s FA Score has 0 green FA rating(s).

  • BIOA’s FA Score: 1 green, 4 red.
  • TLRY’s FA Score: 0 green, 5 red.
According to our system of comparison, BIOA is a better buy in the long-term than TLRY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIOA’s TA Score shows that 4 TA indicator(s) are bullish while TLRY’s TA Score has 4 bullish TA indicator(s).

  • BIOA’s TA Score: 4 bullish, 4 bearish.
  • TLRY’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, BIOA is a better buy in the short-term than TLRY.

Price Growth

BIOA (@Pharmaceuticals: Generic) experienced а +3.28% price change this week, while TLRY (@Pharmaceuticals: Generic) price change was -3.18% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.85%. For the same industry, the average monthly price growth was -2.19%, and the average quarterly price growth was +12.81%.

Reported Earning Dates

BIOA is expected to report earnings on Mar 19, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.85% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TLRY($887M) has a higher market cap than BIOA($842M). BIOA YTD gains are higher at: 52.305 vs. TLRY (-15.836). BIOA has higher annual earnings (EBITDA): -74.68M vs. TLRY (-2.09B). TLRY (292M) and BIOA (286M) have equal amount of cash in the bank . BIOA has less debt than TLRY: BIOA (7.13M) vs TLRY (320M). TLRY has higher revenues than BIOA: TLRY (837M) vs BIOA (5.92M).
BIOATLRYBIOA / TLRY
Capitalization842M887M95%
EBITDA-74.68M-2.09B4%
Gain YTD52.305-15.836-330%
P/E Ratio1.48N/A-
Revenue5.92M837M1%
Total Cash286M292M98%
Total Debt7.13M320M2%
FUNDAMENTALS RATINGS
BIOA vs TLRY: Fundamental Ratings
BIOA
TLRY
OUTLOOK RATING
1..100
7063
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
54
Fair valued
PROFIT vs RISK RATING
1..100
59100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
3465
P/E GROWTH RATING
1..100
694
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIOA's Valuation (54) in the Chemicals Specialty industry is in the same range as TLRY (54) in the Biotechnology industry. This means that BIOA’s stock grew similarly to TLRY’s over the last 12 months.

BIOA's Profit vs Risk Rating (59) in the Chemicals Specialty industry is somewhat better than the same rating for TLRY (100) in the Biotechnology industry. This means that BIOA’s stock grew somewhat faster than TLRY’s over the last 12 months.

BIOA's SMR Rating (96) in the Chemicals Specialty industry is in the same range as TLRY (98) in the Biotechnology industry. This means that BIOA’s stock grew similarly to TLRY’s over the last 12 months.

BIOA's Price Growth Rating (34) in the Chemicals Specialty industry is in the same range as TLRY (65) in the Biotechnology industry. This means that BIOA’s stock grew similarly to TLRY’s over the last 12 months.

BIOA's P/E Growth Rating (6) in the Chemicals Specialty industry is significantly better than the same rating for TLRY (94) in the Biotechnology industry. This means that BIOA’s stock grew significantly faster than TLRY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIOATLRY
RSI
ODDS (%)
Bearish Trend 2 days ago
56%
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
22%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 23 days ago
82%
Bullish Trend 23 days ago
81%
Declines
ODDS (%)
Bearish Trend 7 days ago
82%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
46%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
BIOA
Daily Signal:
Gain/Loss:
TLRY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BIGRX40.460.17
+0.42%
American Century Discplnd Cor Val Inv
SVXYX82.12N/A
N/A
Smead International Value Y
HFESX59.82-0.59
-0.98%
Janus Henderson European Focus S
LIGCX10.57-0.12
-1.12%
Loomis Sayles International Growth C
EGFFX24.24-0.43
-1.74%
Edgewood Growth Retail

BIOA and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIOA has been loosely correlated with AMRX. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if BIOA jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIOA
1D Price
Change %
BIOA100%
+1.21%
AMRX - BIOA
55%
Loosely correlated
+1.26%
DVAX - BIOA
51%
Loosely correlated
+0.19%
TEVA - BIOA
51%
Loosely correlated
-3.56%
UPC - BIOA
50%
Loosely correlated
-3.09%
TLRY - BIOA
49%
Loosely correlated
-2.31%
More

TLRY and

Correlation & Price change

A.I.dvisor indicates that over the last year, TLRY has been closely correlated with ASRT. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if TLRY jumps, then ASRT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLRY
1D Price
Change %
TLRY100%
-2.31%
ASRT - TLRY
77%
Closely correlated
-1.17%
SNDL - TLRY
76%
Closely correlated
-1.89%
TEVA - TLRY
68%
Closely correlated
-3.56%
DVAX - TLRY
65%
Loosely correlated
+0.19%
OGI - TLRY
63%
Loosely correlated
-1.27%
More